Purpose Of Review: Refractory germ cell tumors (GCT), those progressing after known effective salvage therapies, carry a dismal prognosis with minimal treatment options of limited efficacy. This review aims to highlight the advances in understanding refractory GCT and review upcoming and active clinical trials with novel therapeutics in development.
Recent Findings: Patients with refractory disease after optimal salvage chemotherapy are rarely cured and should be referred to centers with expertise in GCT. While prior investigational agents have not overcome current limitations of salvage therapy, current and upcoming trials of novel agents including tyrosine kinase inhibitors (TKI), chimeric antigen receptor (CAR) T-cell therapies, bispecific T-cell engagers (BiTE), and antibody-drug conjugates (ADC) are promising avenues of therapy.
Summary: Outcomes in refractory GCT remain poor. Patients should preferably be evaluated at tertiary care centers with expertise in the management of these patients and access to clinical trials of novel therapeutics. Active research in the understanding of the molecular mechanisms of resistance and targeting of uniquely expressed antigens has broadened the potential therapies in development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCO.0000000000001129 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancing Tumor Microenvironment Analysis: A Fluorescence Nanosystem for Caspase-1 Monitoring and Synergistic Therapy.
Anal Chem
March 2025
College of Chemistry, Jilin Province Research Center for Engineering and Technology of Spectral Analytical Instruments, Jilin University, Qianjin Street 2699, Changchun 130012, China.
The lack of precise, real-time analytical tools for monitoring tumor microenvironment changes during treatment hinders advancements in integrated diagnostic and therapeutic platforms. Traditional caspase-3 monitoring strategies are limited by their inability to address drug resistance and newly discovered apoptotic pathways, leading to reduced accuracy and practicality. To overcome these limitations, we developed a fluorescence-based "Trojan horse" nanosystem, PFpR@CM, featuring high-sensitivity Caspase-1 detection, tumor-targeted delivery, and photothermal therapy.
View Article and Find Full Text PDFImpact of Neoadjuvant and Adjuvant Pleural Intensity-Modulated Radiotherapy in Multimodality Treatment for Malignant Pleural Mesothelioma.
Thorac Cancer
March 2025
Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Background: Few malignancies provoke as many controversies about treatment as pleural mesothelioma. There is limited experience with novel radiotherapy techniques worldwide in adjuvant and particularly in neoadjuvant settings within multimodality treatment. The objective of the current study was to investigate the long-term outcome of neoadjuvant and adjuvant pleural intensity-modulated radiotherapy (IMRT) combined with macroscopic complete resection with or without chemotherapy.
View Article and Find Full Text PDFNovel predictors of infection-related rehospitalization in older patients with heart failure in Japan.
Geriatr Gerontol Int
March 2025
Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Aim: Rehospitalization of patients with heart failure (HF) incurs high health care costs and increased mortality. Infection-related rehospitalizations in patients with HF occur frequently, and the risk increases with age. This study aimed to identify the factors associated with infection-related rehospitalizations in older patients with HF.
View Article and Find Full Text PDFUnlocking the Gates: A Novel Diagnostic Molecule for Quantifying Efflux Levels in Gram-Positive Bacteria.
Adv Healthc Mater
March 2025
Aix Marseille Université, INSERM, SSA, MCT, Marseille, 13385, France.
Efflux-mediated antibiotic resistance poses a significant global threat, affecting diverse bacterial species. Clinicians recognize the danger of efflux mechanisms during antibiotic treatment, yet precise diagnostic tools remain unavailable. The antibiogram currently infers abnormal efflux pump activity in clinical isolates, which is subsequently confirmed through transcriptomic or genomic analysis.
View Article and Find Full Text PDFFLOT1 Is a Novel Serum Biomarker of Ovarian Cancer Targeted by N6-methyladenosine Modification Inhibition.
Cell Biol Int
March 2025
Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, China.
Ovarian cancer (OC) is a deadly disease and lacks a precise marker for diagnosis worldwide. Our previous work has shown the overexpression of flotillin-1 (FLOT1) in OC tissue. To improve diagnostic sensitivity and accuracy, we evaluated the serum level of FLOT1 in OC patients and found that the serum concentration of FLOT1 as well as CA125 was significantly increased in patients with OC compared with healthy control (p < 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!